Scientific Program

3rd World Congress on

Hepatitis and Liver Diseases

October 10-12, 2016 Dubai, UAE

Supporting Sponsors
## Day 1 October 10, 2016

### Conference Series.com

#### Opening Ceremony

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:05</td>
<td>Registrations</td>
<td></td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>09:30-09:35</td>
<td>Title: Possible Role of Estrogen Receptors in Gender Susceptibility in the Development of Chronic Infections and Liver Cancers</td>
<td>Anil Kaul, Oklahoma State University, USA</td>
</tr>
<tr>
<td>10:15-10:55</td>
<td>Title: Nucleic Acid Polymers: broad spectrum antiviral agents and their development as the backbone of new antiviral therapies for the treatment of chronic HBV and HBV / HDV infection</td>
<td>Andrew Vaillant, Replicor Inc, Canada</td>
</tr>
</tbody>
</table>

### Panel Discussion

**Group Photo:** 10:55-11:00

**Networking & Refreshment Break:** 11:00-11:20 @ Foyer

**Session:**

- **Hepatitis Care and Cure | Hepatitis B | Hepatitis C | Hepatitis Vaccination | Liver Diseases**
  - **Session Chair:** Andrew Vaillant, Replicor Inc, Canada
  - **Session Co-chair:** Asad I Dajani, ADSC, United Arab Emirates

**Workshop on Increase of specific social score EPICES before and after direct antiviral agent treatment in HCV patients in France: 2 years experience**

- **Bouchkira Hakim & Andre-Jean Remy,** Perpignan Hospital, France

**Lunch Break:** 13:00-13:45 @ Market Place

### Keynote Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-12:30</td>
<td>Title: Hepatitis C Virus (HCV) genotype 1b as a risk factor for hepatocellular carcinoma development in chronic HCV positive patients in Southern Italy</td>
<td>Arnolfo Petruzziello, IRCCS, Italy</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Title: Direct acting antivirals; are they truely the last nails in the coffin of HCV ??</td>
<td>Fatma Abdelaziz Amer, Zagazig University, Egypt</td>
</tr>
<tr>
<td>13:45-14:15</td>
<td>Title: Nucleic Acid Polymers: Application in the treatment of chronic HBV and HBV / HDV infection and potentiating the effects of immunotherapy</td>
<td>Andrew Vaillant, Replicor Inc, Canada</td>
</tr>
<tr>
<td>14:15-14:45</td>
<td>Title: Direct-acting antivirals Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naive or treatment-experienced patients with or without cirrhosis</td>
<td>Ligita Jancoriene, Vilnius University Hospital, Lithuania</td>
</tr>
<tr>
<td>14:45-15:15</td>
<td>Title: Current therapeutic approaches to NAPLD treatment</td>
<td>Asad I Dajani, Arab Doctors Specialist, UAE</td>
</tr>
<tr>
<td>15:15-15:45</td>
<td>Title: Hepatitis B revaccination to students whom firstly demonstrated anti-HBs negative or titer &lt;10 mIU/ml</td>
<td>Prapan Jutavijittum, Chiang Mai University, Thailand</td>
</tr>
</tbody>
</table>

**Networking & Refreshment Break:** 15:45-16:05 @ Foyer

### Session Introduction

**Session:**

- **Hepatitis Care and Cure | Hepatitis B | Hepatitis C | Hepatitis Vaccination | Liver Diseases**
  - **Session Chair:** Andrew Vaillant, Replicor Inc, Canada
  - **Session Co-chair:** Asad I Dajani, ADSC, United Arab Emirates

### Day 2 October 11, 2016

#### Keynote Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:05</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>09:05-09:45</td>
<td>Title: Hepatitis C virus (HCV) infection: A global epidemiology up-date of the circulation of HCV genotypes</td>
<td>Arnolfo Petruzziello, National Cancer Institute, Italy</td>
</tr>
</tbody>
</table>
09:45-10:25  
**Title:** Sepsis in Cirrhotics  
*Alaaeldin Ibrahim,* ACDS, UAE  
Panel Discussion  
Networking and Refreshments 10:25-10:45 @ Foyer

10:45-11:45  
**Workshop on Economic Evaluation in Health and Medicine**  
*Nermeen Nabil Ashoush,* The British University in Egypt, Egypt  
Sessions:  
Genetic and Metabolic Liver Diseases | Liver Disease Diagnosis | Liver Cancer | Non-Viral Hepatitis | Drug discovery for treatment of Hepatitis  
Session Chair: Anil Kaul, Oklahoma State University, USA  
Session Co-chair: Andre-Jean Remy, Perpignan Hospital, France

### Session Introduction

**Title:** Hepatitis mobile team: A new concept for benefit toward drugs users and precarious people with hepatitis C in France  
*Andre-Jean Remy,* Perpignan Hospital, France

**Title:** Treating patients with hepatitis C genotype 1 using Viekira Pak™ in the real world: An Australian nursing perspective  
*Vince Fragomeli,* Nepean Hospital, Australia

**Title:** New Insights into the Roadmap of Pathogenesis of Liver Fibrosis  
*Eman El-Ahwany,* Theodor Bilharz Research Institute, Egypt

### Lunch Break 13:15-14:00 @ Market Place  
**Poster Presentations 14:00-14:45 @ Foyer**

**HP-001**  
**Title:** CT arterial enhancement fraction (AEF) for hepatocellular carcinoma (HCC) screening in patients with end-stage liver cirrhosis  
*Andreas Christe,* University Hospital of Bern, Switzerland

**Title:** The association of genetic variation near interleukin 28B and UCKL-1 protein expression in liver tissue of patients with hepatitis C induced hepatocellular carcinoma  
*Arida Buivydiene,* Vilnius University, Lithuania

**Title:** Impact of different polymorphisms of IL 10 in prevalence of liver fibrosis and progression in hepatitis C patients  
*Ali Rahman,* University Hospital of Bern, Switzerland

**Title:** PHF20-mediated SREBP regulation is required for the enhancement of lipogenesis and hepatic steatosis in PHF20 transgenic mice  
*Jisoo Park,* Chungnam National University, South Korea

**Title:** Suggested function of Tabebuia avellanedae extract on alcoholic fatty liver disease  
*Hyunj Lee,* Chungnam National University, South Korea

**Title:** Matrine as a new treatment for hepatosteatosis by suppressing ER stress-associated de novo lipogenesis  
*Ali Mahzari,* RMIT University, Australia

**Title:** Beliefs and knowledge about cancer among educated women in Riyadh, Saudi Arabia  
*Shayma Asrar,* Al-Maarefa Colleges, KSA

**Title:** 40 years observation in Liver diseases in the Middle East  
*Makki H Fayadh,* ACDS, UAE

**Title:** Genetics in hepatitis B  
*Osama Hasan Othman,* University of Kirkuk, Iraq

**Title:** Matrine eliminates hepatosteatosis and glucose intolerance in high fructose-fed mice by suppressing ER stress associated de novo lipogenesis in the liver  
*Ali Mahzari,* RMIT University, Australia

### Networking & Refreshment Break 16:15-16:35 @ Foyer

**Title:** We can beat the frightening ghost, HCC  
*Medhat El-Hosary,* Kafr elsheikh Liver Research Center, Egypt

**Title:** Hepatitis B Antigen Quantification  
*Salem Awadh,* Advanced Center for Day Care Surgery LLC, UAE

### Panel Discussion

Awards Ceremony  
Day 3 October 12, 2016

Extended Networking Session & Lunch 12:00-13:30 @ Market Place  
Closing Ceremony